Freya Meds presents a straightforward proposition: online weight-management care, medication delivered to your door and continuing access to a clinician. The harder question is what happens after you agree to pay. Its homepage promotes month-to-month care without lock-in, while treatment pages also offer quarterly billing and delivery. Those arrangements need not be incompatible, but they create different financial exposures—and the consulted documentation does not explain how cancellation affects money already collected.
This review examines Freya through that contractual lens, using public pages consulted October 19, 2026. It separates advertised services from the responsibilities assigned in the terms, preserves the different published prices and identifies questions to settle before checkout. Freya documents a GLP-1 telehealth offering, not merely a referral directory. Nevertheless, neither its marketing nor its legal documents provide a complete account of renewal mechanics, refunds or the exact medication a particular patient would receive.
At a glance
- Two sets of advertised prices
- The homepage lists semaglutide starting as low as $150 per month and tirzepatide starting as low as $249. Treatment pages show higher monthly and quarterly-billed rates; the connection between these offers is unexplained.
- Platform versus clinical care
- The terms describe Freya as a nonclinical administrative and technology provider. Clinical decisions belong to independent licensed healthcare providers working through affiliated professional entities.Sources: [5]
- Geographic restriction
- Although the homepage claims patients across all 50 states, the terms exclude Alabama, Mississippi and West Virginia and limit services to people located in the United States.
- Direct payment
- Freya and its affiliated entities say they do not accept commercial insurance or participate in Medicare or Medicaid. The terms make users responsible for associated professional, laboratory and pharmacy charges.Sources: [5]
Start with the payment interval, not the headline price
Freya publishes several prices that should not be collapsed into one representative monthly cost. The homepage says semaglutide starts as low as $150 per month and tirzepatide as low as $249 per month. The treatment pages instead show semaglutide at $250 per month with quarterly billing and delivery, or $297 for monthly plans; tirzepatide is $332 per month with quarterly billing and delivery, or $390 for monthly plans. These are separate advertised arrangements, not a confirmed personal quote.
The quarterly wording matters because a monthly-equivalent figure does not establish a monthly collection schedule. Conversely, the monthly plans are a documented alternative: quarterly payment should not be described as mandatory for every customer. The pages do not establish the exact formulation, administration route, presentation or quantity attached to each price. References elsewhere to syringes and vials do not resolve those product details. A quarterly delivery interval also does not, by itself, establish a minimum contractual commitment.
The homepage additionally advertises up to $272 off three-month plans at checkout, ending October 31 without specifying a year. Its applicability cannot be confirmed from that banner. Before authorizing payment, request the actual first charge, billing interval and subsequent charge in writing, with the product identified. Our guide to monthly prices and billing commitments explains why the displayed rate and the amount collected can be different questions.
| Advertised option | Published price | Condition or unresolved point |
|---|---|---|
| Homepage semaglutide | Starting as low as $150 per month | Conditions for obtaining this minimum are not explained. |
| Homepage tirzepatide | Starting as low as $249 per month | Relationship to treatment-page prices is not explained. |
| Semaglutide treatment page | $250 per month quarterly; $297 per month monthly | Quarterly option is billed and delivered quarterly. |
| Tirzepatide treatment page | $332 per month quarterly; $390 per month monthly | Quarterly option is billed and delivered quarterly. |
| Three-month promotion | Up to $272 off at checkout | October 31 end date has no year; current applicability is unconfirmed. |
Cancellation language leaves the financial exit unfinished
The homepage advertises no waitlists, no membership fees and no lock-in, describing care as month to month. The semaglutide treatment page separately says customers can cancel anytime. Those are useful commercial statements, but they do not answer whether cancellation stops the next billing event, a pharmacy order already underway or the remaining services within a prepaid quarter. The documents should not be read as promising all three outcomes.
The consulted documentation does not establish automatic-renewal rules, a cancellation channel, a notice deadline or the treatment of unused quarterly payments. It also does not explain what happens to a payment if a clinician declines to prescribe. That last question matters because Freya explicitly says not everyone qualifies. An assessment advertised as requiring no commitment is not enough to determine when a later financial obligation begins or becomes nonrefundable.
A useful pre-enrollment request would ask Freya to identify the next charge date, how to stop it and what happens to any prescription or shipment already authorized. Keep the response with the checkout terms. The distinction between cancellation and refund boundaries is especially important here: permission to end future service does not establish a right to recover an earlier payment. The missing detail is a reason to clarify the arrangement, not proof that refunds are unavailable.
The brand, clinician and pharmacy have different roles
Freya's legal description is more specific than its consumer-facing promise of medically guided care. The terms identify FREYA MEDS International Inc. and affiliates as the website operator, although the document's heading uses FREYA MEDS INC. They describe Freya as a nonclinical administrative and technology management service provider to independent, state-licensed professional corporations. Freya says it does not practice medicine or employ or contract with healthcare providers to deliver clinical services.
Under that structure, the patient-provider relationship for diagnosis, treatment and prescribing is solely with the independent licensed healthcare provider practicing through an affiliated entity. The consulted pages do not name those professional corporations, the responsible individual clinicians or dispensing pharmacies. That does not establish that these parties are absent; it means a prospective customer cannot identify the complete service chain from this documentation alone. Request their names before treating the brand as the answer to every responsibility question.
The terms also provide for individual binding arbitration in English, subject to exceptions described in the document. That is a dispute provision, not evidence about languages available during care. For practical preparation, mapping platform, clinician and pharmacy responsibilities can help distinguish an account problem from a prescribing decision or a dispensing issue. Freya's structure makes that distinction particularly relevant when asking who can authorize a refund, change treatment or resolve a delivery complaint.
What the advertised package includes—and what the terms reserve
Freya lists substantial support alongside medication. The homepage advertises free shipping, monthly live expert sessions with questions and answers, and unlimited clinician and care-team access. The treatment-page comparison lists medication, unlimited doctor consultations, monthly group calls and a one-on-one dietitian consultation. Other program descriptions add nutrition plans, meal guidance, lifestyle coaching, habit-building tools and progress tracking through a personalized dashboard. These are provider-described inclusions, not independently tested service experiences.
The pricing explanation is narrower than an unconditional all-inclusive guarantee: Freya says the price usually includes medication, syringes, shipping, consultations and support. Meanwhile, the terms assign users responsibility for associated charges, including healthcare-provider, laboratory and pharmacy services, with payments handled by third-party processors. The consulted documents do not settle whether laboratory testing is required or whether any such testing would be included. A written itemization would reconcile the marketing bundle with that broader allocation of responsibility.
Freya also says payment covers the full monthly treatment plan rather than a specific vial, and that the cost stays the same regardless of the clinician's individual dose determination. That is a statement about its plan pricing, not identification of the product or a complete explanation of future renewal prices. The treatment page's no-price-changes slogan likewise does not supply detailed contractual price-protection terms. Ask which services and charges your particular checkout amount covers, rather than assuming every possible service is included.
Enrollment is conditional, and coverage claims need qualification
Freya describes a confidential initial assessment covering health, goals and lifestyle, advertised without commitment. Its homepage says a licensed healthcare provider reviews health history, current medicines, weight-loss goals and the overall medical profile before deciding whether treatment is appropriate. The terms limit the intended users to adults 18 or older. The semaglutide page discusses a BMI of 27 or above as a preferred profile, but that marketing description is not an exhaustive eligibility rule or a promise of acceptance.
Location is an unusually important discrepancy. The homepage claims more than 450,000 patients across all 50 states. The terms, however, expressly exclude Alabama, Mississippi and West Virginia, saying residents cannot complete checkout for services. They also limit the service to people located in the United States. The nationwide patient claim should therefore not be used as evidence of current nationwide availability. Someone considering enrollment should resolve location eligibility before relying on a quoted price or appointment expectation.
Payment is explicitly direct-pay. Freya and the affiliated entities say they do not accept commercial health insurance, are not in-network with commercial plans and do not participate in Medicare or Medicaid. That describes the service's payment arrangement; it does not establish an individual insurance plan's reimbursement rules. The documents also advertise same-day physician review and prescription confirmation, but eligibility remains conditional. Same-day review should not be read as a guaranteed prescription, shipment or arrival date.
Product identification must precede assumptions about approval
Freya advertises semaglutide and tirzepatide, while its terms contemplate compounded medication when an independent prescriber considers it appropriate. Those terms acknowledge that compounded preparations are not reviewed or approved by FDA for safety, efficacy or manufacturing quality. They also disclaim guarantees by Freya and its affiliated entities about compounded medication safety, efficacy, purity or quality. These provisions deserve attention, but they do not identify what any particular customer will actually be prescribed or dispensed.
The missing product details are material: exact formulation, route, presentation and compounded status remain unresolved for each priced offering. Comparisons with the active ingredients in Ozempic, Wegovy, Mounjaro or Zepbound do not establish that those brands are supplied or that a dispensed preparation has their approval status. A useful written GLP-1 quote should identify the actual medicine and dispensing pharmacy, not merely repeat an ingredient name and monthly rate.
FDA recommends compounded drugs when an individual's medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Compounded preparations are not FDA approved; that fact alone does not demonstrate clinical inequivalence or establish a provider-specific outcome. FDA also reports measurement and administration errors involving compounded medication. Questions about instructions belong with the prescriber or pharmacist, not a pricing review. No clinical trial result is used here as evidence of Freya's performance.
Pharmacy choice and delivery promises have boundaries
The terms allow a patient with a prescription to select a partner pharmacy in the Freya network. They also describe using a pharmacy of the patient's choice when that option is presented during the service. That qualification matters: the documents do not establish an unrestricted outside-pharmacy pathway at every stage. Nor do they explain whether choosing another pharmacy changes the package price, shipping arrangement or responsibility for resolving an order problem.
Freya advertises free, discreet shipping, and the treatment pages use a fast three-day shipping slogan. The tirzepatide page says medication is delivered properly stored and ready to use. However, the consulted documentation does not explain when the three-day clock starts, whether it describes dispatch or arrival, or the full payment-to-delivery timeline. Carrier, tracking, replacement procedures and cold-chain packaging are also unspecified. These are separate questions from the advertised same-day clinical review.
One concrete packaging disclosure is easy to miss: medications fulfilled through the Freya pharmacy network will not arrive in child-resistant packaging, according to the terms. They instruct users to keep medication out of children's reach. Separately, FDA advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. Freya's general storage assurance does not replace a clear process for reporting and resolving a questionable shipment.
Continuing support needs a usable contact and records pathway
Freya advertises continuity with the same doctor from start to finish, weekly check-ins and direct practitioner messaging. The semaglutide page directs patients who experience problems to contact their practitioner, who may change the clinical approach based on their response. These statements describe more than a one-time prescription transaction. Still, the consulted documentation does not establish guaranteed response times, the mechanics of weekly contacts or what happens if the assigned practitioner becomes unavailable.
For administrative contact, the privacy policy lists contact@freyameds.com, 30 N Gould St Ste R, Sheridan, WY 82801, and hours of 8 a.m. to 8 p.m. Eastern, Monday through Sunday. Published business hours should not be confused with a clinical response guarantee. The terms explicitly exclude emergency care and direct people experiencing a medical emergency to call 911 and seek immediate treatment. Unlimited access therefore should not be interpreted as an emergency-care service.
The records pathway is comparatively specific. Patients can request transfer of their telehealth record by emailing doctor@freyameds.com with consent and the receiving provider's name, address and phone number. The privacy policy also describes access, correction, deletion and certain processing restrictions, subject to applicable law, through the general contact email. These routes are useful for continuity or departure, although they do not supply a cancellation procedure or establish how quickly a request will be completed.
Questions & answers
Can I obtain Freya's $150 semaglutide or $249 tirzepatide price?
The homepage advertises those starting monthly amounts, but the consulted documentation does not explain qualifying conditions. Treatment pages show different monthly and quarterly-billed rates. Ask for the exact product, first charge, later charges and applicable promotion before relying on either minimum. The public prices are not a confirmed individualized offer.
Does canceling a quarterly plan return the unused payment?
The consulted documents do not answer that question. Freya advertises cancellation anytime and quarterly billing, but does not establish how unused prepaid amounts are handled. Ask separately about stopping renewal, stopping an order already in progress and obtaining a refund. Those are different outcomes, and the cancellation slogan does not promise all of them.
Is Freya available in every state?
Not according to the consulted terms. Despite the homepage's claim of patients across 50 states, the terms exclude Alabama, Mississippi and West Virginia and say residents cannot check out for services. Services are also limited to people located in the United States. Confirm current availability for your location rather than relying on the nationwide marketing claim.
Will Freya bill my insurance?
Its terms say Freya and the affiliated entities do not accept commercial insurance and are not enrolled in Medicare or Medicaid. Enrollment is cash-pay. The documents also assign users responsibility for associated professional, laboratory and pharmacy charges. Ask which charges your particular plan includes; do not assume the general package description resolves every possible expense.
Can I use my own pharmacy?
The terms describe choosing a Freya network pharmacy or a pharmacy of your choice when that option is presented during use of the service. They do not establish that outside fulfillment is available at every point or explain its effect on package pricing. Confirm the dispensing pharmacy and any changed costs before an order is authorized.
How can I send my Freya record to another clinician?
The terms direct patients to email doctor@freyameds.com with consent and the other healthcare provider's name, address and phone number. For general administrative or privacy questions, the published address is contact@freyameds.com. A records-transfer request is not described as canceling the plan, so address any billing or cancellation request separately and retain confirmation.
Our assessment
Freya documents a substantial service proposition: clinician assessment, potential prescribing, home delivery, continuing messaging and nutrition-related support, with both monthly and quarterly-priced options. Its terms also usefully distinguish the technology platform from independent clinical care. The principal weakness for a prospective customer is incomplete financial exit information alongside inconsistent price presentations and geographic messaging. Before paying, obtain a written checkout summary identifying the product, responsible clinical entity, dispensing pharmacy, included charges, renewal schedule and cancellation/refund treatment. Clear answers could make the arrangement easier to evaluate; the current public documentation alone does not settle those commitments or establish treatment outcomes.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.